Lineage Cell Therapeutics updates shelf offering to sell up to $38.9M in common shares

Lineage Cell Therapeutics, Inc.

Offering up to $38,856,704 of common shares under previously effective Form S-3 registration statement.
Prospectus supplement filed May 18, 2023, updating the Controlled Equity Offering agreement with Cantor Fitzgerald & Co.
Legal opinion from Sheppard, Mullin, Richter & Hampton LLP on share validity included as exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.